Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine plus 131I-MIBG for relapsed or progressive pediatric neuroblastoma
NL-OMON24917Phase 2Recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Sep 2010
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gemcitabine and Iobenguane I-131 in neuroblastoma, sponsored by Amsterdam University Medical Center. Primary endpoints: Efficacy as measured by response rate and Time-to-event measurements. Started Sep 2010; status: recruiting.
02
Drugs
gemcitabineIobenguane I-131
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on NL-OMON24917.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON24917.